Intravenous iron: an update

被引:9
作者
Lucas, Sarah [1 ]
Garg, Mayur [1 ,2 ,3 ]
机构
[1] Univ Melbourne, Northern Hlth, Melbourne, Vic, Australia
[2] Univ Melbourne, Dept Med, Melbourne, Vic, Australia
[3] Northern Hlth, Dept Gastroenterol, 185 Cooper St, Melbourne, Vic 3076, Australia
关键词
iron; ferric caboxymaltose; ferric derisomaltose; iron deficiency; intravenous iron; QUALITY-OF-LIFE; HEART-FAILURE; FERRIC CARBOXYMALTOSE; DEFICIENCY; ANEMIA; DIAGNOSIS; SUPPLEMENTS; ABSORPTION; MECHANISMS; GUIDELINES;
D O I
10.1111/imj.16184
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Iron deficiency is the most common nutritional deficiency worldwide, with significant adverse health consequences in the presence or absence of anaemia. Total dose intravenous iron replacement is recommended for replacement of iron in patients with severe iron deficiency, especially in the presence of anaemia, intolerance or inefficacy following oral iron, or states of inflammation where upregulation of hepcidin may impair gastrointestinal absorption of iron. Currently, available intravenous iron formulations have been demonstrated to have an excellent overall safety profile, but potential adverse effects, including skin staining, infusion-related reactions and hypophosphataemia, have been described. Knowledge of differences in administration and safety profiles of currently available iron formulations will allow appropriate prescription, counselling, as well as recognition and management of adverse events in patients requiring intravenous iron.
引用
收藏
页码:26 / 34
页数:9
相关论文
共 65 条
  • [51] Impaired intestinal iron absorption in Crohn's disease correlates with disease activity and markers of inflammation
    Semrin, Gaith
    Fishman, Douglas S.
    Bousvaros, Athos
    Zholudev, Anna
    Saunders, Andrew C.
    Correia, Catherine E.
    Nemeth, Elizabeta
    Grand, Richard J.
    Weinstein, David A.
    [J]. INFLAMMATORY BOWEL DISEASES, 2006, 12 (12) : 1101 - 1106
  • [52] British Society of Gastroenterology guidelines for the management of iron deficiency anaemia in adults
    Snook, Jonathon
    Bhala, Neeraj
    Beales, Ian L. P.
    Cannings, David
    Kightley, Chris
    Logan, Robert Ph
    Pritchard, D. Mark
    Sidhu, Reena
    Surgenor, Sue
    Thomas, Wayne
    Verma, Ajay M.
    Goddard, Andrew F.
    [J]. GUT, 2021, 70 (11) : 2030 - 2051
  • [53] Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials
    Stoffel, Nicole U.
    Cercamondi, Colin I.
    Brittenham, Gary
    Zeder, Christophe
    Geurts-Moespot, Anneke J.
    Swinkels, Dorine W.
    Moretti, Diego
    Zimmermann, Michael B.
    [J]. LANCET HAEMATOLOGY, 2017, 4 (11): : E524 - E533
  • [54] Safety of Intravenous Iron Following Infusion Reactions
    Stojanovic, Stephanie
    Graudins, Linda, V
    Aung, Ar Kar
    Grannell, Louise
    Hew, Mark
    Zubrinich, Celia
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2021, 9 (04) : 1660 - 1666
  • [55] Hypersensitivity to intravenous iron: classification, terminology, mechanisms and management
    Szebeni, J.
    Fishbane, S.
    Hedenus, M.
    Howaldt, S.
    Locatelli, F.
    Patni, S.
    Rampton, D.
    Weiss, G.
    Folkersen, J.
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2015, 172 (21) : 5025 - 5036
  • [56] Hypocalcaemia and hypophosphataemia following denosumab and IV ferric carboxymaltose in an older patient with normal renal function
    Tai, Rebecca
    Mouchaileh, Nadia
    Ting, Celia
    [J]. JOURNAL OF PHARMACY PRACTICE AND RESEARCH, 2022, 52 (01) : 49 - 52
  • [57] Therapeutic Goods Administration, VEN IR SUC INT AUSTR
  • [58] Therapeutic Goods Administration, 2024, Database of Adverse Event Notifications (DAEN)-medicines
  • [59] Therapeutic Guidelines, 2022, OR IR SUPPL
  • [60] Therapeutic Guidelines, 2022, INTR IR SUPPL